(Reuters Health)—The incidence of hip fractures in older women in the U.S. is rising after more than a decade of decline, according to a large new study of Medicare recipients. Hip fracture rates declined each year from 2002–2012, the researchers found. But starting in 2013, hip fracture rates leveled off and were higher than expected….
Search results for: musculoskeletal disease

Incoming ACR President Dr. David Daikh Considers Serving Organization an Honor and Privilege
Following the 2017 ACR/ARHP Annual Meeting when the formal transition in volunteer leadership occurred, my overwhelming thought has been that it is an honor and privilege to serve you as the 81st president of the ACR. Honor stems from the heritage of excellence and progress that defines this organization. Privilege comes from the opportunity to…

What Makes an Effective Department Head?
If you’re aspiring to lead a rheumatology department, you will need more than what you learned in medical school. Beyond expertly treating patients and participating in research, these leaders must also understand management, mentorship and problem solving, as well as the business of running a successful department…

Rheumatology Health Professionals’ Awards, Appointments and Announcements November 2017
Dr. Sherine Gabriel Joins Board of Trustees In July, ACR Past President Sherine E. Gabriel, MD, MSc, joined the New York Academy of Medicine Board of Trustees. Dr. Gabriel is a distinguished professor and dean of Rutgers Robert Wood Johnson Medical School. As dean emerita of Mayo Medical School, Dr. Gabriel developed successful clinical research training and career development…

Infiltrating the Disc: Mast Cells & Back Pain
Mast cells may become a therapeutic target for low back pain, according to new research. Researchers found mast cells can infiltrate intervertebral disc cells and play a role in their degeneration. Specifically, mast cells and the cytokine, IL-6, were both more likely to be found in painful intervertebral discs surgically removed from patients than in control discs…

2017 Update of Treat-to-Target Recommendations for Axial & Peripheral SpA & PsA
An international task force has updated recommendations for axial and peripheral spondyloarthritis, and psoriatic arthritis, which include treat-to-target recommendations…

Prospects for Treating Patients with Arthritis in African Countries with Few Rheumatologists
At present, the U.S. has approximately 5,000 full-time adult rheumatologists. By the year 2025, that number will decline to roughly 3,600.1 Sounds dire, right? Hold that thought. Question: What country has 99 million people and no adult rheumatologists? Answer: Ethiopia.2 The Nigerian Story And then there is Africa’s most populous country, Nigeria, with roughly 170…

On the Road in Rajasthan: Vehicular-Caused Bone, Joint Damage in India
In the good old days, physicians routinely made house calls. The decision to visit the literal bedside of a patient was practical: hospital services were primitive and often offered too little benefit to justify an emergency journey by the patient. These physicians carried leather bags, sometimes called Gladstones, that were filled with instruments for eventualities…
ACR, EULAR Approve New Classification Criteria for Primary Sjögren’s Syndrome
Classification criteria for primary Sjögren’s syndrome (SS) have been approved by the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR), validating an international set of classification criteria for SS using standards set by both organizations. Those criteria can now be found in the 2016 ACR/EULAR Classification Criteria for Primary Sjögren’s Syndrome: A…

Potential Benefits, Pitfalls of Biosimilars Reviewed at EULAR 2016
LONDON—The availability of a biosimilar form of infliximab has dramatically increased the number of Norwegians taking one form or another of the drug, an expert on biosimilars said in a debate-style session at the Annual Congress of the European League Against Rheumatism (EULAR 2016). The expanded uptake of Remicade (infliximab) and its biosimilar, Remsima (international…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 93
- Next Page »